Carcinoma, Neuroendocrine
"Carcinoma, Neuroendocrine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)
| Descriptor ID |
D018278
|
| MeSH Number(s) |
C04.557.465.625.650.240 C04.557.470.200.025.370 C04.557.580.625.650.240
|
| Concept/Terms |
Carcinoma, Neuroendocrine- Carcinoma, Neuroendocrine
- Carcinomas, Neuroendocrine
- Neuroendocrine Carcinoma
- Neuroendocrine Carcinomas
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Neuroendocrine".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Neuroendocrine".
This graph shows the total number of publications written about "Carcinoma, Neuroendocrine" by people in this website by year, and whether "Carcinoma, Neuroendocrine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 1 | 2 |
| 1999 | 4 | 1 | 5 |
| 2000 | 4 | 0 | 4 |
| 2001 | 1 | 1 | 2 |
| 2002 | 1 | 1 | 2 |
| 2003 | 3 | 0 | 3 |
| 2004 | 4 | 0 | 4 |
| 2005 | 2 | 1 | 3 |
| 2006 | 3 | 0 | 3 |
| 2007 | 8 | 0 | 8 |
| 2008 | 6 | 2 | 8 |
| 2009 | 2 | 2 | 4 |
| 2010 | 6 | 2 | 8 |
| 2011 | 10 | 5 | 15 |
| 2012 | 5 | 1 | 6 |
| 2013 | 6 | 4 | 10 |
| 2014 | 7 | 7 | 14 |
| 2015 | 9 | 2 | 11 |
| 2016 | 15 | 0 | 15 |
| 2017 | 15 | 2 | 17 |
| 2018 | 8 | 3 | 11 |
| 2019 | 9 | 1 | 10 |
| 2020 | 11 | 2 | 13 |
| 2021 | 11 | 3 | 14 |
| 2022 | 10 | 2 | 12 |
| 2023 | 14 | 0 | 14 |
| 2024 | 10 | 4 | 14 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoma, Neuroendocrine" by people in Profiles.
-
Impact of systemic therapy on clinical T1 small-cell neuroendocrine carcinoma of the bladder. ESMO Open. 2024 Nov; 9(11):103964.
-
YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities. Clin Cancer Res. 2024 Oct 15; 30(20):4743-4754.
-
A Phase I Open-Label Study of Cediranib Plus Etoposide and Cisplatin as First-Line Therapy for Patients With Extensive-Stage Small-Cell Lung Cancer or Metastatic Neuroendocrine Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2024 Nov; 25(7):601-611.
-
Pediatric Medullary Thyroid Carcinoma: Clinical Presentations and Long-Term Outcomes in 144 Patients Over 6 Decades. J Clin Endocrinol Metab. 2024 Aug 13; 109(9):2256-2268.
-
Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001. J Clin Oncol. 2024 Sep 20; 42(27):3187-3195.
-
The Multi-Institutional Medullary Thyroid Cancer Collaborative Registry: Can a Rare Tumor Registry Accurately Represent the Real-World Patient Population? Thyroid. 2024 Sep; 34(9):1117-1125.
-
TPPP-BRD9 fusion-related gallbladder carcinomas are frequently associated with intracholecystic neoplasia, neuroendocrine carcinoma, and a distinctive small tubular-type adenocarcinoma commonly accompanied with a syringomatous pattern. Hum Pathol. 2024 08; 150:67-73.
-
Reply to Letter to the Editor regarding "Decreased utilization for postoperative radiation therapy in locoregionally advanced medullary thyroid cancer". Head Neck. 2024 07; 46(7):1848-1849.
-
Neuroendocrine neoplasms of the ovary: a review of 63 cases. Int J Gynecol Cancer. 2024 Apr 01; 34(4):566-573.
-
Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy. Endocr Relat Cancer. 2024 Apr 01; 31(4).